What is the Role of Measuring Urinary Gluten Immunogenic Peptides in Clinical Practice in Patients with Coeliac Disease?
Journal of Gastrointestinal and Liver Diseases · 2024
DOI: 10.15403/jgld-5659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2024. Verfasst von Suneil A Raju und 10 weiteren Autor:innen. Beteiligte Einrichtung: Academic Unit of Gastroenterology, Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield; Division of Clinical Medicine, S…. Hauptthemen laut MEDLINE: Celiac Disease, Glutens, Biomarkers, Predictive Value of Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: In coeliac disease, the clinical role of the urinary gluten immunogenic peptide is unclear. It has been suggested it can be a non-invasive marker of villous atrophy. Therefore, we present the largest cross-sectional clinical data in patients with coeliac disease to establish the diagnostic accuracy of the urinary gluten immunogenic peptide in identifying villous atrophy.
Methods
Patients providing urinary gluten immunogenic peptide were identified between September 2018 and August 2023 at the National Health Service (NHS) England National Centre for Non-Responsive and Refractory CD. In our retrospective study, the results of the urinary gluten immunogenic peptide test collected within 7 days, self-reported adherence to a gluten free diet reported within 3 months, serology collected within 7 days (immunoglobulin A - tissue transglutaminase and endomysial antibody) and histology at the time of endoscopy were compared in individuals with coeliac disease who were either asymptomatic and undergoing remission biopsies (group 1), non-responsive coeliac disease (group 2) and refractory coeliac disease on immunosuppressive therapy (group 3). Associations between dichotomous variables were calculated using chi-squared test.
Results
In group 1 the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for detecting villous atrophy were 42.9%, 83.3.%, 64.3% and 67.6% respectively. In group 2 the sensitivity, specificity, PPV and NPV for detecting villous atrophy were 36.2%, 79.0%, 39.5% and 76.6% respectively. In group 3 the sensitivity, specificity, PPV and NPV for detecting villous atrophy were 56.3%, 70.6%, 73.0% and 53.3%. More patients on immunosuppression had a positive urinary gluten immunogenic peptide than those not on immunosuppression (43.3% vs 24.1%, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Academic Unit of Gastroenterology, Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Shef…
- Department of Neurology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, United Kingdom. m.hadjivassiliou@nhs.net.
- Immunology Department, Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, United Kingdom. graeme.wild1@nhs.net.
Zitieren
APA
Raju, S. A., Ingham, K. E., Green, O., Johnson, C. M., Shiha, M. G., Nandi, N., Trott, N., Penny, H. A., Hadjivassiliou, M., Wild, G., & Sanders, D. S. (2024). What is the Role of Measuring Urinary Gluten Immunogenic Peptides in Clinical Practice in Patients with Coeliac Disease?. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-5659
Vancouver
Raju SA, Ingham KE, Green O, Johnson CM, Shiha MG, Nandi N, et al. What is the Role of Measuring Urinary Gluten Immunogenic Peptides in Clinical Practice in Patients with Coeliac Disease?. Journal of Gastrointestinal and Liver Diseases. 2024. doi:10.15403/jgld-5659
BibTeX
@article{Raju2024,
author = {Raju, Suneil A and Ingham, Katerina E and Green, Olivia and Johnson, Calvin M and Shiha, Mohamed G and Nandi, Nicoletta and Trott, Nick and Penny, Hugo A and Hadjivassiliou, Marios and Wild, Graeme and Sanders, David S},
title = {What is the Role of Measuring Urinary Gluten Immunogenic Peptides in Clinical Practice in Patients with Coeliac Disease?},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2024},
doi = {10.15403/jgld-5659}
}
EUVIMED